B7-33 6 mg – Peptide Hubs
B7-33 is a synthetic peptide and selective analog of human relaxin-2, specifically designed to target and activate the RXFP1 receptor with minimized hormonal activity. The 6 mg lyophilized vial by Peptide Hubs offers researchers a highly stable, precise format for studying fibrotic conditions, cardiac and pulmonary remodeling, and wound healing responses.
What Is B7-33?
B7-33 is a single-chain variant of relaxin-2 that retains anti-fibrotic signaling via the RXFP1 receptor without triggering the reproductive or vasodilatory side effects typical of native relaxin. It is considered a promising candidate in the field of organ fibrosis, particularly in liver, heart, and lung tissues. Researchers value B7-33 for its ability to modulate TGF-β1 signaling and reduce tissue scarring.
Mechanism of Action
B7-33 selectively binds to the relaxin family peptide receptor 1 (RXFP1), stimulating downstream signaling pathways that reduce fibrotic activity and collagen deposition. Unlike full relaxin-2, it does not activate secondary receptors tied to systemic vasodilation or reproductive hormones. This selectivity makes B7-33 ideal for studies focused on anti-fibrotic outcomes. For in-depth biological data, see this NIH publication on B7-33.
Research Applications
B7-33 is used in preclinical research involving organ protection, tissue remodeling, and systemic or localized fibrotic disorders. It has been studied in models of myocardial infarction, pulmonary fibrosis, and kidney injury. Some experimental protocols also examine B7-33's synergy with compounds like BPC-157 and GHK-CU for regenerative medicine research.
Technical Details
Peptide Type
Single-Chain Relaxin-2 Analogue
Peptide Sequence
VIKLSGRELVRAQIAISGMSTWSKRSL
Peptide Length
27 Amino Acids
Calculated Molecular Mass
2986.6 Da
Structural Format
Single-Chain Linear Peptide
Signaling Profile
pERK1/2-Biased RXFP1 Agonist
Development Status
Experimental / Preclinical
Dosage & Usage Guidelines
- Dose: 3–6 mg/day depending on application
- Administration: Subcutaneous injection
- Duration: 7–20 days, based on tissue regeneration goals
In inflammation-related protocols, researchers also co-administer ARA-290 or Semax for broader neuroprotective or anti-inflammatory effects.
Stacking Combinations
To enhance the research outcomes of B7-33 in tissue recovery and wound repair, common combinations include:
- BPC-157 – muscle and tendon healing
- GHK-CU – for skin and collagen regeneration
- AOD 9604 – metabolic support in post-injury studies
Side Effects & Legality
B7-33 is not associated with hormonal side effects or estrogenic activity. It is non-toxic to the liver and does not influence androgenic pathways, blood pressure, or aromatization. B7-33 is strictly sold for research purposes and is not FDA-approved for human use. For trial data and safety info, refer to the ClinicalTrials.gov database.
Shipping & Product Authenticity
USA Domestic
4–5 business days
International
13–15 business days
Order Processing
24–48 business hours
Tracking
Tracking number provided
Direct Supply & Discreet Delivery
This product is supplied through the official Peptide Hubs distribution chain and shipped in original manufacturer packaging. The outer shipping package remains discreet, with privacy-focused handling and no unnecessary external product details.
What to Expect
- ✔ Orders are processed after payment confirmation
- ✔ USA Domestic shipping is typically faster when local stock is selected
- ✔ International orders include tracking, though update frequency may vary by destination
- ✔ Multiple warehouses may result in separate shipments when applicable
Authenticity support: official Peptide Hubs presentation, batch-linked lab proof, and original packaging help reinforce product legitimacy and buyer confidence.
Verified Supply
For complete delivery details, tracking policy, and reshipment terms, please see our Shipping Info page.
Storage
Store the lyophilized powder at controlled room temperature (15–25°C) in a dry, dark place, away from direct light and moisture. The unopened vial should be kept in its original packaging to maintain stability.
After reconstitution, store the solution at 2–8°C and use within 14 days. Do not freeze. Discard any unused portion after the recommended storage period. Before use, inspect the solution and avoid use if it appears cloudy, discolored, or contains particulate matter, or if the vial or seal is compromised.
Keep out of reach of children. Follow proper handling and sterile injection practices during research use.
Proper storage conditions help maintain product stability and consistent performance across the product's shelf life.
Frequently Asked Questions
What is B7-33 used for in research?
B7-33 is studied for its anti-fibrotic effects in organ protection, wound healing, and tissue remodeling, particularly in heart, liver, and lung research models.
How does B7-33 work?
B7-33 binds to the RXFP1 receptor and activates anti-fibrotic signaling pathways, reducing TGF-β1 activity and preventing excess collagen buildup.
Is B7-33 a hormone or does it affect estrogen?
No, B7-33 is a selective analog of relaxin-2 and does not have hormonal side effects like vasodilation or estrogenic influence.
Can B7-33 be used with other peptides?
Yes, B7-33 is often stacked with BPC-157, GHK-CU, or ARA-290 for research on enhanced tissue healing or fibrosis reduction.
No reviews found
Please log in to write B7-33 6 mg review.